Natco Pharma [NATCOPHARM] vs Neuland Laboratories [NEULANDLAB] Detailed Stock Comparison

Natco Pharma Ltd.

NSE
Loading...

Neuland Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Natco Pharma Ltd. wins in 15 metrics, Neuland Laboratories Ltd. wins in 5 metrics, with 0 ties. Natco Pharma Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Natco Pharma Ltd. Neuland Laboratories Ltd. Better
P/E Ratio (TTM) 12.32 103.42 Natco Pharma Ltd.
Price-to-Book Ratio 2.22 11.41 Natco Pharma Ltd.
Debt-to-Equity Ratio 3.01 16.33 Natco Pharma Ltd.
PEG Ratio 0.89 -1.72 Natco Pharma Ltd.
EV/EBITDA 9.10 347.81 Natco Pharma Ltd.
Profit Margin (TTM) 34.13% 2.29% Natco Pharma Ltd.
Operating Margin (TTM) 17.38% 12.10% Natco Pharma Ltd.
EBITDA Margin (TTM) 17.38% 12.10% Natco Pharma Ltd.
Return on Equity 24.77% 17.06% Natco Pharma Ltd.
Return on Assets (TTM) 21.85% 11.93% Natco Pharma Ltd.
Free Cash Flow (TTM) $11.85B $1.11B Natco Pharma Ltd.
Dividend Yield 0.73% 0.08% Natco Pharma Ltd.
1-Year Return 15.00% 48.55% Neuland Laboratories Ltd.
Price-to-Sales Ratio (TTM) 4.21 30.51 Natco Pharma Ltd.
Enterprise Value $162.40B $185.79B Neuland Laboratories Ltd.
EV/Revenue Ratio 3.56 30.67 Natco Pharma Ltd.
Gross Profit Margin (TTM) 79.44% 44.60% Natco Pharma Ltd.
Revenue per Share (TTM) $255 $515 Neuland Laboratories Ltd.
Earnings per Share (Diluted) $86.97 $139.29 Neuland Laboratories Ltd.
Beta (Stock Volatility) 0.19 -0.32 Neuland Laboratories Ltd.

Natco Pharma Ltd. vs Neuland Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

NATCOPHARM
NEULANDLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Natco Pharma Ltd.-0.51%-20.80%-15.73%-1.77%0.72%5.75%
Neuland Laboratories Ltd.0.49%-0.95%4.87%29.12%3.39%12.28%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Natco Pharma Ltd.15.00%61.82%-2.35%95.99%1,726.50%4,758.44%
Neuland Laboratories Ltd.48.55%510.11%716.28%2,058.53%16,354.50%19,900.00%

Performance & Financial Health Analysis: Natco Pharma Ltd. vs Neuland Laboratories Ltd.

MetricNATCOPHARMNEULANDLAB
Market Information
Market Cap i₹191.91B₹184.81B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i701,46433,181
90 Day Avg. Volume i888,16939,837
Last Close₹934.50₹16,992.00
52 Week Range₹789.00 - ₹1,226.80₹11,500.00 - ₹19,747.00
% from 52W High-23.83%-13.95%
All-Time High₹1,639.00 (Sep 09, 2024)₹19,747.00 (Nov 10, 2025)
% from All-Time High-42.98%-13.95%
Growth Metrics
Quarterly Revenue Growth0.36%0.11%
Quarterly Earnings Growth0.14%-0.60%
Financial Health
Profit Margin (TTM) i0.34%0.02%
Operating Margin (TTM) i0.17%0.12%
Return on Equity (TTM) i0.25%0.17%
Debt to Equity (MRQ) i3.0116.33
Cash & Liquidity
Book Value per Share (MRQ)₹482.88₹1,262.78
Cash per Share (MRQ)₹178.93₹131.49
Operating Cash Flow (TTM) i₹19.26B₹3.44B
Levered Free Cash Flow (TTM) i₹18.85B₹2.60B
Dividends
Last 12-Month Dividend Yield i0.73%0.08%
Last 12-Month Dividend i₹6.50₹12.00

Valuation & Enterprise Metrics Analysis: Natco Pharma Ltd. vs Neuland Laboratories Ltd.

MetricNATCOPHARM (Apr 24, 2026)NEULANDLAB (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i12.32103.42
Forward P/E i27.2642.60
PEG Ratio i0.89-1.72
Price to Sales (TTM) i4.2130.51
Price to Book (MRQ) i2.2211.41
Market Capitalization
Market Capitalization i₹191.91B₹184.81B
Enterprise Value i₹162.40B₹185.79B
Enterprise Value Metrics
Enterprise to Revenue i3.5630.67
Enterprise to EBITDA i9.10347.81
Risk & Other Metrics
Beta i0.19-0.32
Book Value per Share (MRQ) i₹482.88₹1,262.78

Financial Statements Comparison: Natco Pharma Ltd. vs Neuland Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNATCOPHARM (2025)NEULANDLAB (2025)
Revenue/Sales i44.12B14.34B
Cost of Goods Sold i8.65B7.51B
COGS % of Revenue i19.6%52.3%
Gross Profit i35.46B6.84B
Gross Margin i80.4%47.7%
Research & Development i1.13BN/A
Operating Income (EBIT) i19.81B2.67B
Operating Margin i44.9%18.6%
EBITDA i24.58B3.41B
EBITDA Margin i55.7%23.8%
Pre-Tax Income i22.91B3.46B
Pre-Tax Income % of Revenue i51.9%24.1%
Income Tax i4.08B862.21M
Income Tax % of Revenue i9.2%6.0%
Net Income (Profit) i18.83B2.60B
Profit Margin i42.7%18.1%

Balance Sheet & Liquidity Metrics

MetricNATCOPHARM (2025)NEULANDLAB (2025)
Cash & Equivalents i1.20B1.32B
Total Current Assets i52.70B11.39B
Total Current Assets % of Revenue i119.5%79.4%
Total Current Liabilities i9.44B4.66B
Total Current Liabilities % of Revenue i21.4%32.5%
Long-Term Debt i46.00M1.09B
Long-Term Debt % of Revenue i0.1%7.6%
Total Shareholders Equity i76.12B15.25B
Retained Earnings i62.47B9.95B
Retained Earnings % of Revenue i141.6%69.3%
Property, Plant & Equipment i474.00M6.74B

Cash Flow Statement Comparison

MetricNATCOPHARM (2025)NEULANDLAB (2025)
Operating Cash Flow i19.26B3.44B
Operating Cash Flow % of Revenue i43.7%24.0%
Capital Expenditures i-3.06B-2.05B
Free Cash Flow i11.85B1.11B
FCF Margin i26.9%7.7%
Debt Repayment iN/A-394.35M
Common Stock Repurchase i0N/A

Short Interest & Institutional Ownership Analysis

MetricNATCOPHARMNEULANDLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i179.11M12.83M
Float Shares i83.44M4.86M
% Held by Insiders i50.55%37.96%
% Held by Institutions i11.35%27.06%
% Held by Public i38.10%34.98%

Dividend Analysis & Yield Comparison: Natco Pharma Ltd. vs Neuland Laboratories Ltd.

MetricNATCOPHARMNEULANDLAB
Last 12-Month Dividend i₹6.50₹12.00
Last 12-Month Dividend Yield i0.73%0.08%
3-Year Avg Annual Dividend i₹7.25₹12.00
3-Year Avg Dividend Yield i0.24%0.20%
3-Year Total Dividends i₹21.75₹36.00
Ex-Dividend DateFeb 18, 2026Jul 18, 2025